Amrize (NYSE:AMRZ) Stock Rated Equal Weight in New Coverage at Barclays

Stock analysts at Barclays initiated coverage on shares of Amrize (NYSE:AMRZ) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm set an “equal weight” rating and a $55.00 price target on the stock. Barclays‘s price target indicates a potential upside of 47.81% from the company’s current price.

Several other equities research analysts also recently weighed in on the company. Truist Financial reiterated a “hold” rating and issued a $48.00 price target (down from $65.00) on shares of Amrize in a report on Tuesday, July 7th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $44.00 price target (down from $55.00) on shares of Amrize in a report on Wednesday, September 9th. Royal Bank Of Canada downgraded Amrize from a “sector perform” rating to an “underperform” rating and reduced their price target for the stock from $60.00 to $48.00 in a report on Monday, August 10th. Citigroup downgraded Amrize from a “buy” rating to a “cautious” rating in a report on Wednesday, September 9th. Finally, Weiss Ratings downgraded Amrize from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Amrize has an average rating of “Hold” and a consensus target price of $51.76.

Amrize Trading Down 0.1%

Shares of NYSE:AMRZ traded down $0.05 during trading on Thursday, hitting $37.21. The company had a trading volume of 2,124,758 shares, compared to its average volume of 3,374,826. The stock has a market cap of $20.58 billion, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20. Amrize has a one year low of $36.55 and a one year high of $65.94. The company has a fifty day simple moving average of $43.64 and a two-hundred day simple moving average of $50.07. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.10 and a quick ratio of 0.73.

Amrize (NYSE:AMRZ) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.04). The company had revenue of $3.49 billion during the quarter. Amrize had a net margin of 9.89% and a return on equity of 10.22%. As a group, equities analysts forecast that Amrize will post 2.46 earnings per share for the current year.

Insider Buying and Selling at Amrize

In related news, CFO Baris Oran bought 3,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were acquired at an average price of $47.38 per share, with a total value of $142,140.00. Following the transaction, the chief financial officer owned 3,000 shares of the company’s stock, valued at $142,140. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jacques Sanche bought 4,150 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were bought at an average cost of $45.02 per share, for a total transaction of $186,833.00. Following the transaction, the director directly owned 9,766 shares in the company, valued at approximately $439,665.32. This represents a 73.90% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 48,983 shares of company stock worth $2,158,755. 0.54% of the stock is currently owned by company insiders.

Institutional Trading of Amrize

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caldwell Sutter Capital Inc. boosted its position in shares of Amrize by 11.5% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 2,675 shares of the company’s stock worth $150,000 after purchasing an additional 275 shares in the last quarter. Baldwin Investment Management LLC boosted its position in shares of Amrize by 4.4% in the 4th quarter. Baldwin Investment Management LLC now owns 8,980 shares of the company’s stock worth $486,000 after purchasing an additional 375 shares in the last quarter. Mengis Capital Management Inc. boosted its position in shares of Amrize by 8.5% in the 4th quarter. Mengis Capital Management Inc. now owns 5,750 shares of the company’s stock worth $311,000 after purchasing an additional 450 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its position in shares of Amrize by 4.3% in the 2nd quarter. Norman Fields Gottscho Capital Management LLC now owns 11,515 shares of the company’s stock worth $614,000 after purchasing an additional 475 shares in the last quarter. Finally, MCF Advisors LLC acquired a new stake in Amrize during the 4th quarter worth about $27,000.

Amrize Company Profile

Amrize Ltd. is a North American building solutions company that produces and supplies essential construction materials and related products. Its portfolio includes cement, aggregates, ready-mix concrete, asphalt, concrete products and roofing systems used in residential, commercial and infrastructure projects.

The company serves customers across the United States and Canada through a network of production facilities, distribution locations and other operating sites. Its products support a range of construction applications, including roads, bridges, buildings, homes and other major infrastructure.

Amrize was established as the result of the separation of Holcim’s North American business and began operating as an independent, publicly traded company in 2025.